Avalyn Pharma
Avalyn is a clinical-stage biotech company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Their goal is to deliver inhaled formulations of effective medicines directly to lung tissue to potentially enhance efficacy and reduce side effects associated with systemic drug delivery.
Industries
Nr. of Employees
small (1-50)
Patents
Specially formulated compositions of inhaled nintedanib and nintedanib salts
US-12090225-B2
View Details
Specially formulated compositions of inhaled nintedanib and nintedanib salts
US-12090225-B2
View DetailsProducts
Clinical-stage inhaled pirfenidone candidate
An inhaled formulation of an antifibrotic agent developed for treatment of pulmonary fibrosis; in clinical development.
Clinical-stage inhaled nintedanib candidate
An inhaled formulation of a tyrosine kinase inhibitor developed for treatment of pulmonary fibrosis; in clinical development.
Preclinical fixed-dose combination inhaled candidate
A preclinical-stage fixed-dose combination of two antifibrotic agents formulated for inhalation to assess combined local activity in the lung.
AP01
An inhaled formulation of pirfenidone delivered via an approved handheld eFlow nebulizer for the treatment of progressive pulmonary fibrosis.
modified eFlow Nebulizer
A vibrating mesh nebulizer system used to administer AP01 inhaled pirfenidone formulations.
AP02
An inhaled formulation of nintedanib designed for direct aerosol lung delivery to slow the progression of idiopathic pulmonary fibrosis (IPF).
Clinical-stage inhaled pirfenidone candidate
An inhaled formulation of an antifibrotic agent developed for treatment of pulmonary fibrosis; in clinical development.
Clinical-stage inhaled nintedanib candidate
An inhaled formulation of a tyrosine kinase inhibitor developed for treatment of pulmonary fibrosis; in clinical development.
Preclinical fixed-dose combination inhaled candidate
A preclinical-stage fixed-dose combination of two antifibrotic agents formulated for inhalation to assess combined local activity in the lung.
AP01
An inhaled formulation of pirfenidone delivered via an approved handheld eFlow nebulizer for the treatment of progressive pulmonary fibrosis.
modified eFlow Nebulizer
A vibrating mesh nebulizer system used to administer AP01 inhaled pirfenidone formulations.
AP02
An inhaled formulation of nintedanib designed for direct aerosol lung delivery to slow the progression of idiopathic pulmonary fibrosis (IPF).
Services
Design and execution of clinical trials focused on inhaled therapies for pulmonary fibrosis and related interstitial lung diseases; includes patient recruitment and trial management.
Preclinical evaluation and development activities to advance inhaled formulations and fixed-dose combinations toward clinical entry.
Resources and policies for patients and caregivers, including information on clinical trials and an expanded access policy for investigational therapies.
Design and execution of clinical trials focused on inhaled therapies for pulmonary fibrosis and related interstitial lung diseases; includes patient recruitment and trial management.
Preclinical evaluation and development activities to advance inhaled formulations and fixed-dose combinations toward clinical entry.
Resources and policies for patients and caregivers, including information on clinical trials and an expanded access policy for investigational therapies.
Expertise Areas
- Inhaled drug development
- Pulmonary/respiratory therapeutics
- Clinical trial management for rare lung diseases
- Formulation development for inhalation
Key Technologies
- Inhaled drug delivery
- Pulmonary-targeted delivery
- Formulation development for inhalation
- Fixed-dose combination inhalation
News & Updates
Avalyn announces a presentation at the European Congress of Rheumatology 2025.
Avalyn to participate in the Jefferies Global Healthcare Conference in June.
Avalyn showcases clinical data across multiple pulmonary fibrosis programs at ATS 2025.
Avalyn announces a presentation at the European Congress of Rheumatology 2025.
Avalyn to participate in the Jefferies Global Healthcare Conference in June.
Avalyn showcases clinical data across multiple pulmonary fibrosis programs at ATS 2025.